Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical pharmaceutical company developing injection-based treatments against chronic pain originating from the intevertebral discs. Stayble currently has one phase 2b project within degenerative disc disease and one phase 1b within disc herniation.

LATEST PRESS RELEASES

September 21, 2023

Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...

September 6, 2023

Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...

FINANCIAL CALENDAR

Interim report Q3 2023
14November2023
Interim report Q4 2023
20February2024